Skip to content
Download PDF

Carcinoma of Unknown Primary

Chapter 97 | Part 4: Oncology and Hematology · Part 4 – Oncology: Solid Tumors · Chapter 97

Key Clinical Points

  1. CUP accounts for 3–5% of all malignancies and is among the 10 most frequently diagnosed cancers globally.
  2. Median survival for disseminated CUP is ~6–10 months; some subsets (e.g., isolated axillary adenopathy) may have prolonged survival.
  3. Standard workup includes CT chest/abdomen/pelvis, mammography in women, and PSA in men with osteoblastic metastases.
  4. IHC panels (CK7, CK20, TTF-1, GATA3) and molecular profiling are critical for identifying putative primary sites.
  5. Treatment is tailored to 'putative primary' based on IHC/molecular data; empiric chemotherapy used for disseminated disease without clear profile.
  6. Bone metastases managed with radiation, bone-seeking radionuclides (Strontium-89, Samarium-153, Radium-223), and bisphosphonates/denosumab.
  7. Intrahepatic cholangiocarcinoma (ICC) is frequently misdiagnosed as CUP; incidence of ICC is rising while CUP is declining.
  8. Targeted therapies (e.g., afatinib for EGFR, pembrolizumab for MSI-H/dMMR) and immunotherapy are increasingly utilized in CUP.
  9. Prognostic factors include performance status, number of metastatic sites, histology, and serum LDH levels.
  10. Molecular profiling (DNA methylation) predicts primary cancer in ~87% of CUP patients; actionable mutations found in ~85% of cases.

DEFINITION & CLASSIFICATION

• Definition (Harrison's 22e): Carcinoma (or cancer) of unknown primary (CUP) is a biopsy-proven malignancy for which the anatomic site of origin remains unidentified after a standardized detailed diagnostic evaluation. • Prevalence: 3–5% of all malignancies; among the top 10 most frequently diagnosed cancers globally. • Patient Population: Occurs in all age groups, including adolescents and young adults. • Diagnostic Evolution: 'Unknown' status is increasingly challenged by advanced imaging, IHC, and genomic tools. • Treatment Paradigm: Shifting from empiricism to personalized therapy via targeted agents and biomarker-driven approaches. • Exclusions: Does not include lymphomas, melanomas, or sarcomas (due to distinct histology/staging guidelines).

ETIOLOGY & PATHOPHYSIOLOGY

• Etiology Hypotheses: Reasons for CUP presentation are unclear; potential reasons include: ◦ Primary tumor regression or undetectable size ◦ Immune containment of primary tumor ◦ Metastatic dominance over primary lesion • Molecular Profile: No distinct molecular signature identified despite genomic profiling. • Genomic Findings: Chromosomal abnormalities (chromosomes 1/12), aneuploidy (70% of metastatic adenocarcinoma/undifferentiated carcinoma), and gene overexpression (RAS, BCL2, HER2, P53) are observed but not unique to CUP. • Research Need: Multiomic studies required to identify CUP-specific molecular drivers. • Intrahepatic Cholangiocarcinoma (ICC): ◦ Often misdiagnosed as CUP due to similar presentations. ◦ Rising ICC incidence correlates with declining CUP rates. ◦ Improved diagnostics (NGS, molecular profiling) and clinician awareness improve recognition.

CLINICAL FEATURES

• Presentation: Metastatic disease without identifiable primary site. • Common Sites: Adenopathy (axillary, cervical, mediastinal), peritoneal carcinomatosis, bone metastases. • Bone Metastases Management: ◦ End-of-life pain: Requires adequate narcotic analgesia. ◦ Radionuclides: Strontium-89, Samarium-153, Radium-223 (provide antitumor effects and symptom relief). ◦ Bone Resorption Inhibition: Denosumab (inhibits osteoclastic activity); bisphosphonates (e.g., pamidronate) reduce bone resorption. ◦ Monitoring: Monitor electrolytes/creatinine during bisphosphonate therapy. ◦ Frequency: Monthly administration may reduce bone metastases in breast cancer patients. ◦ Prophylaxis: Internal fixation indicated for weight-bearing bone compromise. • Hormonal Response: Hormonally responsive tumors (prostate/breast) respond to hormone inhibition. • Curable Exceptions: Bone metastases from lymphoma or Hodgkin's lymphoma are curable.

Bone Metastases Specifics

• Pain Management: End-of-life bone pain requires adequate narcotic analgesia. • Radiopharmaceuticals: Strontium-89, Samarium-153, Radium-223 exert antitumor effects and relieve symptoms. • Pharmacotherapy: Denosumab inhibits osteoclastic activity; bisphosphonates (pamidronate) reduce bone resorption. ◦ Monitoring: Monitor electrolytes/creatinine during bisphosphonate therapy. ◦ Frequency: Monthly administration may reduce bone metastases in breast cancer patients. • Surgical Intervention: Prophylactic internal fixation indicated for weight-bearing bone compromise.

DIFFERENTIAL DIAGNOSIS

• Diagnostic Status: Diagnosis of exclusion after standardized evaluation. • Latent Primaries: Included in <5% of CUP patients; seen in indolent presentations with responsive metastases. • Common Misdiagnosis: ICC is frequently misidentified as CUP. • Exclusions: Lymphomas, melanomas, and sarcomas are excluded due to distinct histology/staging guidelines.

DIAGNOSTIC APPROACH

• Primary Goals: Identify primary/putative primary via clinicopathologic evaluation and determine disease extent. • Clinical Evaluation: ◦ Focused evaluation based on clinical clues to optimize testing. ◦ Detailed history (risk factors, prior surgeries, family history). ◦ Physical exam (Digital rectal exam in men; breast/pelvic exams in women). • Imaging Studies: 1. CT chest/abdomen/pelvis: Mandatory for all patients. 2. Mammography: For women with axillary lymphadenopathy. 3. MRI Breast: If mammography/ultrasound negative (negative result predicts low mastectomy yield). 4. Cervical CUP Workup: CT/MRI, laryngoscopy, bronchoscopy, endoscopy, tonsillectomy. 5. 18-FDG-PET: Useful for biopsy guidance, extent, and treatment planning (identifies ~21–30% head/neck primaries in cervical CUP). 6. PET-CT: Helpful for bone metastases and multimodality therapy candidates. • Tumor Markers: ◦ CEA, CA-125: Non-specific. ◦ PSA: Used for osteoblastic metastases. ◦ β-hCG/AFP: Elevation suggests extragonadal germ cell tumors. • Pathologic Evaluation: 1. Mandatory detailed evaluation (H&E, IHC, molecular profiling). 2. IHC Panels: CK7, CK20, TTF-1, GATA3 are critical for identifying putative primaries. 3. Molecular Profiling: DNA methylation predicts primary site in ~87% of cases; identifies actionable mutations in ~85% (TP53 55%, KRAS 20%, CDKN2A 19%, ARID1A 11%). • Histology Distribution: 1. Adenocarcinoma: 60–65%. 2. Squamous cell carcinoma: 5%. 3. Poorly differentiated adenocarcinoma/carcinoma: 30–35%. 4. Neuroendocrine: 2%. 5. Undifferentiated malignancy: 3%. Reference Table 97-1 for specific proportions. • IHC Profiles: 1. CK7: Positive in lung, ovary, endometrium, breast, upper GI tract. 2. CK20: Positive in gastrointestinal, urothelial, Merkel cells. 3. CDX-2: Gastrointestinal adenocarcinomas (also mucinous ovarian). 4. TTF-1: Lung/thyroid cancers (68% of adenocarcinomas, 25% squamous lung). 5. GCDFP-15: Apocrine differentiation in breast (62–72%). 6. GATA3: Useful for metastatic breast carcinoma (especially triple-negative/metaplastic). 7. UROIII/CK20: Urothelial origin markers. Reference Table 97-2 for full list of IHC stains by primary type.

IHC Interpretation (Figure 97-1)

• CK7/CK20 Logic Tree: 1. CK7(+) → CK20(+): Urothelial, Ovarian mucinous, Pancreatic, or Cholangiocarcinoma. 2. CK7(+) → CK20(-): Lung, Breast, Thyroid, Endometrial, Cervical, Salivary gland, Cholangiocarcinoma, or Pancreatic carcinoma. 3. CK7(-) → CK20(+): Colorectal carcinoma or Merkel cell carcinoma. 4. CK7(-) → CK20(-): Hepatocellular, Renal cell, Prostate, Squamous/Small-cell lung, or Head and neck carcinoma.

MANAGEMENT & TREATMENT

• General Strategy: Tailored to 'putative primary' based on IHC/molecular data. • Empiric Therapy: Used for disseminated disease without clear profile (e.g., paclitaxel/carboplatin, gemcitabine/cisplatin). • Targeted Therapies: 1. Afatinib: Effective in EGFR-mutant CUP (progression-free survival >6 months). 2. Pembrolizumab: Used for MSI-H/dMMR. 3. NTRK inhibitors: For specific mutations. • Tumor-Agnostic Therapies: Pembrolizumab (MSI-H/dMMR) and NTRK inhibitors benefit a small minority of CUP patients. • Liquid Biopsies: ctDNA used for non-invasive mutation detection. • Bone Metastases Management: 1. Radiation. 2. Bone-seeking radionuclides (Strontium-89, Samarium-153, Radium-223). 3. Bisphosphonates/Denosumab. • Specialized Pathways (Figure 97-3): 1. Squamous Cell CUP: a. Disseminated/Visceral: Directed invasive tests → Chemotherapy (C) if good performance; RT as indicated. b. Inguinal Adenopathy: Perineal exam, anoscopy, pelvic exam, PET (optional). If localized → lymph node dissection + adjuvant RT. c. Cervical Adenopathy: Triple endoscopy, consider esophagectomy; CT neck/chest; PET (optional). i. No extra-cervical disease → Neck dissection + adjuvant RT vs. RT alone. ii. Bulky disease → Chemotherapy (C) for bulky disease. 2. Adenocarcinoma/Poorly Diff (Figure 97-2): a. Axillary Nodes: i. If MRI/Mammo/US negative & PSA not elevated → C or RT as indicated. ii. If MRI positive (+) → Breast surgery or radiation; C and/or hormonal therapy. iii. If MRI negative (-) → No surgery, consider radiation; C for breast cancer. b. Bone Metastases: i. Check PSA (tumor and serum). If elevated → Rx as prostate cancer. c. Solitary Site: i. If resectable → Resect with or without prior C or CRT. ii. If unresectable → C, RT, or CRT depending on location. d. Peritoneal Carcinoma: i. Not suggestive of primary peritoneal → GI workup; C if good performance. ii. Suggestive of primary peritoneal → Treat as ovarian cancer. e. Disseminated (≥ 2 sites): C, if good performance status.

Favorable CUP Subsets

• Isolated axillary adenopathy: May have prolonged survival. • Molecularly defined subgroups: e.g., EGFR-mutant tumors respond to targeted therapies.

Targeted Therapies & Molecular Profiling

• Actionable Mutations: Identified in ~85% of samples (TP53 55%, KRAS 20%, CDKN2A 19%, ARID1A 11%). • Pathway Drivers: Adenocarcinoma CUP more frequently driven by RTK/Ras/MAPK pathway alterations. • Liquid Biopsies: ctDNA enables non-invasive mutation detection.

PROGNOSIS & COMPLICATIONS

• Median Survival: ~6–10 months for disseminated CUP. • Prognostic Factors: 1. Performance status. 2. Number of metastatic sites. 3. Histology. 4. Serum LDH levels. • Molecular Impact: Identification of subgroups with better outcomes (e.g., EGFR-mutant tumors).

KEY PEARLS & HIGH-YIELD POINTS

• Not a Single Entity: CUP is a diagnostic category, not a single disease. • IHC Utility: CK7/CK20 patterns are practical for identifying putative primaries despite lack of prospective validation. • ICC Awareness: Rising ICC incidence correlates with declining CUP rates; always rule out primary peritoneal or biliary sources. • Molecular Advantage: Molecular profiling improves targeting over empiricism and identifies actionable mutations in ~85% of cases. • Liquid Biopsy: ctDNA is a viable non-invasive tool for identifying targetable mutations.

Reference Tables

TABLE 97-1 Major Histologies in Carcinoma (Cancer) of Unknown Primary HISTOLOGY Well to moderately differentiated…

Harrison's 22e, p.732

HISTOLOGY PROPORTION, %
Well to moderately differentiated adenocarcinoma 60
Poorly differentiated adenocarcinoma, poorly
differentiated carcinoma		 30
Undifferentiated malignancy 3

TABLE 97-2 Select Immunohistochemical Stains Useful in the Diagnosis of

Harrison's 22e, p.733

LIKELY PRIMARY PROFILE COMMONLY CONSIDERED IHC TO ASSIST IN
DIFFERENTIAL DIAGNOSIS OF CUPa
Breast ER, GCDFP-15, mammaglobin, HER2/neu, GATA3
Lung adenocarcinoma TTF-1; nuclear staining, napsin A, SP-A1
Prostate PSA, α-methylacyl CoA racemase/P504S (AMACR/
P504S), P501S (prostein), PSMA, NKX3-1
Neuroendocrine Chromogranin, synaptophysin, CD56
Renal RCC, CD10, PAX8, CD10
Melanoma S100, SOX-10, vimentin, HMB-45, tyrosinase,
melan-A
Mesothelioma Calretinin, WT1, D2-40, mesothelin
SCC p63, p40 (lung SCC), CK5/6